# AKTS (Aktis Oncology, Inc.) - SEC EDGAR Financial Statements

> Aktis Oncology, Inc. reported $532.5M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/AKTS
- Markdown: https://convexityos.com/fundamentals/AKTS.md
- SEC CIK: 0002035832
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:31 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002035832&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $68.32M | Total debt: $10.84M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $3.90M | $3.38M | $3.23M | $1.58M | $1.60M | $1.45M |
| Research & Development | $32.12M | $25.28M | $20.04M | $16.47M | $18.63M | $15.86M |
| Total Operating Expenses | $38.65M | $32.28M | $25.93M | $19.78M | $22.56M | $19.59M |
| **Operating Income** | -$34.75M | -$28.90M | -$22.71M | -$18.20M | -$20.96M | -$18.14M |
| **EBITDA** | -$33.80M | -$28.02M | -$22.05M | -$17.61M | -$20.41M | -$17.66M |
| Interest Income | $4.82M | $4.76M | $4.38M | $2.68M | $2.91M | $3.17M |
| **Net Income** | -$29.94M | -$24.14M | -$18.32M | -$15.53M | -$18.07M | -$14.98M |
| Basic EPS | -$0.54 | -$0.44 | -$0.38 | -$19.18 | -$22.39 | -$18.60 |
| **Diluted EPS** | -$0.54 | -$0.44 | -$0.38 | -$19.18 | -$22.39 | -$18.60 |
| Basic Shares Outstanding | 55.6M | 55.3M | 48.6M | 809.8K | 807.3K | 805.8K |
| Diluted Shares Outstanding | 55.6M | 55.3M | 48.6M | 809.8K | 807.3K | 805.8K |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $68.32M | $82.49M | $371.6M | $37.78M |
| **Cash & Short-Term Investments** | $492.9M | $517.3M | $538.5M | $37.78M |
| **Total Current Assets** | $499.9M | $524.5M | $543.9M | $230.3M |
| Property, Plant & Equipment, Net | $15.37M | $15.97M | $15.29M | $14.60M |
| **Total Non-Current Assets** | $32.60M | $33.06M | $32.86M | $34.58M |
| **Total Assets** | $532.5M | $557.6M | $576.8M | $264.9M |
| Accounts Payable | $1.44M | $2.53M | $1.23M | $1.74M |
| Deferred Revenue (Current) | $15.23M | $17.34M | $18.96M | $18.66M |
| **Total Current Liabilities** | $35.16M | $32.13M | $27.91M | $31.24M |
| Deferred Revenue (Non-Current) | $29.07M | $30.87M | $32.63M | $36.16M |
| **Total Non-Current Liabilities** | $38.45M | $40.63M | $42.78M | $46.39M |
| **Total Liabilities** | $73.61M | $72.76M | $70.69M | $77.62M |
| **Total Debt (incl. Leases)** | $10.84M | $11.24M | $11.58M | $11.55M |
| Retained Earnings | -$229.0M | -$199.0M | -$174.9M | -$156.6M |
| Accumulated Other Comp. Income | -$1.93M | -$745K | -$241K | $42K |
| **Total Stockholders' Equity** | $458.9M | $484.8M | $506.1M | -$146.1M |
| Total Equity | $458.9M | $484.8M | $506.1M | -$146.1M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$29.94M | -$24.14M | -$18.32M | -$15.53M | -$18.07M | -$14.98M |
| Depreciation & Amortization | $942K | $879K | $652K | $598K | $552K | $484K |
| Stock-Based Compensation | $3.45M | $3.22M | $3.02M | $1.28M | $1.52M | $1.24M |
| Change in Payables | -$667K | $866K | -$65K | $392K | -$115K | $90K |
| **Operating Cash Flow** | -$26.05M | -$20.59M | -$24.24M | -$15.22M | -$16.18M | -$17.48M |
| Capital Expenditure | -$772K | -$1.26M | -$1.85M | -$2.00M | -$1.53M | -$1.89M |
| **Free Cash Flow** | -$26.82M | -$21.85M | -$26.10M | -$17.23M | -$17.71M | -$19.38M |
| Purchases of Investments | -$56.24M | -$300.4M | $0 | $0 | $0 | -$10.82M |
| **Investing Cash Flow** | $10.17M | -$268.7M | $20.54M | $85.23M | $68.14M | $39.04M |
| Common Stock Issued | -- | -- | $5.38M | -- | -- | -- |
| **Financing Cash Flow** | $1.71M | $156K | $337.5M | $28K | $0 | -$468K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 14.22x | 16.33x | 19.49x | -- | -- | -- |
| Quick Ratio | 14.02x | 16.10x | 19.29x | -- | -- | -- |
| Debt to Equity | 0.02x | 0.02x | 0.02x | -- | -- | -- |
| **Revenue Growth (YoY)** | +147.3% | +111.4% | +123.0% | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
